About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

UNC‐Chapel Hill and Deerfield Management announce the creation of Pinnacle Hill to accelerate the discovery of new medicines

Deerfield Management commits up to $65 million to support the development of novel therapeutics at UNC‐Chapel Hill

(Chapel Hill, N.C. and New York, N.Y. – October 22, 2018) – The University of North Carolina at Chapel Hill and Deerfield Management have entered into a partnership to create Pinnacle Hill, LLC., a company seeking to discover new medicines to address the significant unmet medical needs of our times. Deerfield has committed $65 million of targeted funding and to provide drug development expertise in support of promising new drug research across a wide range of therapeutic areas.

“This is a very exciting new partnership between UNC‐Chapel Hill and Deerfield Management. In creating a new company, Pinnacle Hill, we are bringing together the best of academia and industry to accelerate innovative drug research,” said Chancellor Carol L. Folt. “By investing in our faculty’s early stage research, this partnership advances our commitment to improving the health and well‐being of people around the world.”

Research and development conducted at Pinnacle Hill will be supported by funding, expert drug development guidance, experienced project management oversight, and business strategy. These efforts will serve to improve and accelerate the product development process and allow founding scientists to concentrate on their research.

Pinnacle Hill will focus on drug research projects that are approved and directed by a joint steering committee comprised of members from UNC‐Chapel Hill and Deerfield leadership teams. Each selected project has the potential to receive funding to support investigational new drug enabling studies. The inaugural UNC members of the joint committee will be:

  • Terry Magnuson, UNC‐Chapel Hill’s vice chancellor for research and the Sarah Graham Kenan professor of genetics
  • Dr. Dhiren Thakker, distinguished professor and interim dean of the UNC Eshelman School of Pharmacy and interim director of the Eshelman Institute for Innovation
  • Dr. Blossom Damania, the Boshamer Distinguished professor of microbiology and immunology and vice dean for research in the UNC School of Medicine

“UNC‐Chapel Hill’s world‐class scientists, research centers and institutes, including the Eshelman Institute for Innovation, have enabled a culture of innovation with a focus on the patient and novel discoveries. This will play a critical role in our collaboration to help solve problems, discover new technologies and hopefully save lives,” stated James Flynn, managing partner of Deerfield Management.

Projects selected for support through Pinnacle Hill will receive a complete development plan with funding to support further research across the UNC‐Chapel Hill campus. UNC‐Chapel Hill’s Eshelman School of Pharmacy and School of Medicine, as well as institutes like the Lineberger Comprehensive Cancer Center and the Eshelman Institute for Innovation have drug discovery teams and core resources to support the development of new therapies to treat a wide variety of unmet medical needs. Deerfield may make additional capital investments in successful projects. Profits from successful projects, if any, will be shared by Deerfield and UNC‐Chapel Hill.

“UNC‐Chapel Hill is home to some of the world’s most innovative and life‐changing research,” said Robert Blouin, executive vice chancellor and provost of UNC‐Chapel Hill. “The new partnership between UNC‐Chapel Hill and Deerfield Management gives us an exciting opportunity to accelerate drug discovery research at the University and advance new therapies that have the potential to improve health in North Carolina and beyond.”

Oct. 12, 2018 marked the 225th anniversary of the University’s founding. Carolina has a rich tradition as a public research university, conducts more than $1 billion in research activity annually and is the eleventh largest U.S. university in research volume and annual expenditures. The collaboration between the University and Deerfield will provide crucial support to accelerate early‐stage research that could improve human health worldwide.

About the University of North Carolina at Chapel Hill

The University of North Carolina at Chapel Hill, the nation’s first public university, is a global higher education leader known for innovative teaching, research and public service. A member of the prestigious Association of American Universities, Carolina regularly ranks as the best value for academic quality in U.S. public higher education. Now in its third century, the University offers 74 bachelor’s, 104 master’s, 65 doctorate and seven professional degree programs through 14 schools including the College of Arts & Sciences. Every day, faculty, staff and students shape their teaching, research and public service to meet North Carolina’s most pressing needs in every region and all 100 counties. Carolina’s nearly 330,000 alumni live in all 50 states, the District of Columbia, US Territories and 162 countries. Almost 178,000 live in North Carolina.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit

University Communications
Audrey Smith, (919) 445‐8555, [email protected]

Deerfield Management Company Communications
Karen Heidelberger, (212) 551‐1600, [email protected]